A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma

被引：6

作者：

Patel, Hiren, V ^{[1
,2
]}

Srivastava, Arnav ^{[1
,2
]}

Srinivasan, Ramaprasad ^{[3
]}

Singer, Eric A. ^{[1
,2
]}

机构：

[1] Rutgers Canc Inst New Jersey, Sect Urol Oncol, New Brunswick, NJ 08903 USA

[2] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA

[3] NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2021年 / 33卷 / 03期

基金：

美国国家卫生研究院;

关键词：

chromophobe; genomics; nonclear cell renal cell carcinoma; papillary; renal cell carcinoma; COMPREHENSIVE MOLECULAR CHARACTERIZATION; PHASE-II; METASTATIC PAPILLARY; INTERFERON-ALPHA; OPEN-LABEL; SUNITINIB; EFFICACY; MUTATIONS; SAFETY; SAVOLITINIB;

D O I：

10.1097/CCO.0000000000000721

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of review As molecular profiling of renal cell carcinoma (RCC) continues to elucidate novel targets for nonclear cell histologies, understanding the landscape of these targets is of utmost importance. In this review, we highlight the genomic landscape of nonclear cell RCC and its implications for current and future systemic therapies. Recent findings Several genomic studies have described the mutational burden among nonclear cell histologies. These studies have highlighted the importance of MET in papillary RCC and led to several clinical trials evaluating the efficacy of MET inhibitors for papillary RCC. The success of immune checkpoint inhibitors, such as ipilimumab and nivolumab, in clear cell RCC has led to ongoing trials evaluating these novel therapeutics in nonclear cell RCC. Genomic profiling has allowed for the evaluation of novel targets for nonclear cell RCC. This evolving therapeutic landscape is being explored in promising, ongoing trials that have the potential for changing how nonclear cell RCC is managed.

引用

页码：212 / 220

页数：9

共 73 条

[1]

Ahrens M, 2020, J CLIN ONCOL, V38

[2] MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array [J].

Albiges, Laurence ;

Guegan, Justine ;

Le Formal, Audrey ;

Verkarre, Virginie ;

Rioux-Leclercq, Nathalie ;

Sibony, Mathilde ;

Bernhard, Jean-Christophe ;

Camparo, Philippe ;

Merabet, Zahira ;

Molinie, Vincent ;

Allory, Yves ;

Orear, Cedric ;

Couve, Sophie ;

Gad, Sophie ;

Patard, Jean-Jacques ;

Escudier, Bernard .

CLINICAL CANCER RESEARCH, 2014, 20 (13) :3411-3421

[3] Evolving Paradigms in the Management and Outcomes of Sarcomatoid Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors [J].

Aly, Ragia ;

Aujla, Amandeep S. ;

Gupta, Sachin ;

Gupta, Ruby ;

Gupta, Sorab ;

Kalathil, Sheila .

WORLD JOURNAL OF ONCOLOGY, 2020, 11 (05) :183-187

[4]

[Anonymous], 2021, NOB MED AB 2021

[5]

[Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 3.2020

[6] Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum [J].

Argani, Pedram ;

Olgac, Semra ;

Tickoo, Satish K. ;

Goldfischer, Michael ;

Moch, Holger ;

Chan, David Y. ;

Eble, John N. ;

Bonsib, Stephen M. ;

Jimeno, Mireya ;

Lloreta, Josep ;

Billis, Athanase ;

Hicks, Jessica ;

De Marzo, Angelo M. ;

Reuter, Victor E. ;

Ladanyi, Marc .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (08) :1149-1160

[7] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Eisen, Tim ;

Broderick, Samuel ;

Stadler, Walter M. ;

Jones, Robert J. ;

Garcia, Jorge A. ;

Vaishampayan, Ulka N. ;

Picus, Joel ;

Hawkins, Robert E. ;

Hainsworth, John D. ;

Kollmannsberger, Christian K. ;

Logan, Theodore F. ;

Puzanov, Igor ;

Pickering, Lisa M. ;

Ryan, Christopher W. ;

Protheroe, Andrew ;

Lusk, Christine M. ;

Oberg, Sadie ;

George, Daniel J. .

LANCET ONCOLOGY, 2016, 17 (03) :378-388

[8] Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights [J].

Carlo, Maria I. ;

Hakimi, A. Ari ;

Stewart, Grant D. ;

Bratslavsky, Gennady ;

Brugarolas, James ;

Chen, Ying-Bei ;

Linehan, W. Marston ;

Maher, Eamonn R. ;

Merino, Maria J. ;

Offit, Kenneth ;

Reuter, Victor E. ;

Shuch, Brian ;

Coleman, Jonathan A. .

EUROPEAN UROLOGY, 2019, 76 (06) :754-764

[9] Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets [J].

Chen, Ying-Bei ;

Xu, Jianing ;

Skanderup, Anders Jacobsen ;

Dong, Yiyu ;

Brannon, A. Rose ;

Wang, Lu ;

Won, Helen H. ;

Wang, Patricia I. ;

Nanjangud, Gouri J. ;

Jungbluth, Achim A. ;

Li, Wei ;

Ojeda, Virginia ;

Hakimi, A. Ari ;

Voss, Martin H. ;

Schultz, Nikolaus ;

Motzer, Robert J. ;

Russo, Paul ;

Cheng, Emily H. ;

Giancotti, Filippo G. ;

Lee, William ;

Berger, Michael F. ;

Tickoo, Satish K. ;

Reuter, Victor E. ;

Hsieh, James J. .

NATURE COMMUNICATIONS, 2016, 7

[10]

Choueiri TK, 2008, J CLIN ONCOL, V26, P127, DOI 10.1200/JCO.2007.13.3223

← 1 2 3 4 5 6 7 8 →